Loading...
Bortezomib Reduces Preexisting Antibodies to Recombinant Immunotoxins in Mice()
Recombinant immunotoxin (RIT) therapy is limited in patients by neutralizing antibody responses. Ninety percent of patients with normal immune systems make neutralizing antibodies after one cycle of RIT, preventing repeated dosing. Furthermore, some patients have preexisting antibodies from environm...
Saved in:
| Published in: | J Immunol |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2015
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4323725/ https://ncbi.nlm.nih.gov/pubmed/25560410 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1402324 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|